Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Details Narrative)

v3.8.0.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Dec. 24, 2017
Nov. 24, 2017
Nov. 10, 2017
Oct. 25, 2017
Oct. 24, 2017
Oct. 20, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Professional fees             $ 186,208 $ 84,038 $ 566,131 $ 161,113
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GenExosome Technologies Inc. [Member]                    
Number of shares acquired       600            
Number of shares issued in business acquisition       500,000            
Total consideration $ 450,000 $ 876,087   $ 1,326,087            
Percentage of voting interests acquired       60.00%            
Subsequent Event [Member] | Asset Purchase Agreement [Member] | GenExosome Technologies Inc. [Member]                    
Percentage of voting interests acquired   60.00%                
Subsequent Event [Member] | Asset Purchase Agreement [Member] | Dr. Zhou [Member] | GenExosome Technologies Inc. [Member]                    
Number of shares acquired   400                
Number of shares issued in business acquisition   500,000                
Total consideration   $ 876,087                
Percentage of voting interests acquired   40.00%                
Subsequent Event [Member] | Stock Purchase Agreement [Member] | Dr. Zhou [Member] | Beijing Jieteng (GenExosome) Biotech Co. Ltd [Member]                    
Total consideration       $ 450,000            
Subsequent Event [Member] | Executive Retention Agreement [Member] | Dr. Zhou [Member] | GenExosome Technologies Inc. [Member]                    
Professional fees       $ 160,000            
Subsequent Event [Member] | October 2017 Private Placement [Member] | Subscription Agreement [Member] | October 2017 Accredited Investors [Member]                    
Number of shares issued           3,750,000        
Value for shares issued     $ 2,090,000   $ 200,000 $ 3,750,000